{
  "ticker": "ATH",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968928",
  "id": "02968928",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0921",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrvzwhzyjppg.pdf",
  "summary": "- **Price Query Response**: No undisclosed material information identified by Alterity Therapeutics to explain recent trading activity.  \n- **Potential Catalyst**: Market anticipation of upcoming Phase 2 data (ATH-201 study) and open-label data (ATH-202 study) due mid-2025.  \n- **Investor Engagement**: Non-Deal Roadshow scheduled for 31 July \u2013 6 August 2025, involving institutional and high-net-worth investor meetings.  \n\n**No material capital markets or trading actions required based on this announcement.**",
  "usage": {
    "prompt_tokens": 2427,
    "completion_tokens": 108,
    "total_tokens": 2535,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T23:32:43.174697"
}